| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -23.45 M USD | -16.53 M USD | -7.45 M USD | -14.97 M USD | -14.50 M USD | -13.55 M USD | -9.86 M USD | -10.77 M USD | -12.33 M USD | -10.77 M USD | -9.60 M USD | -9.03 M USD |
| Depreciation & Amortization | — | — | — | 0 USD | 93416 USD | 103168 USD | 97915 USD | 110371 USD | 67981 USD | 25000 USD | 23269 USD | 566262 USD |
| Stock-Based Compensation | 1.45 M USD | 1.41 M USD | 407632 USD | 928052 USD | 897260 USD | 736119 USD | 515762 USD | 1.22 M USD | 1.24 M USD | 1.39 M USD | 2.10 M USD | 1.61 M USD |
| Capital Expenditures | — | — | — | — | — | — | — | — | 447823 USD | 2331 USD | 28227 USD | 50911 USD |
| Cash Flow from Investing | 18.10 M USD | -28.66 M USD | 0 USD | -12.24 M USD | 4000 USD | 0 USD | — | — | -447823 USD | 8.50 M USD | -278227 USD | -50911 USD |
| Cash Flow from Financing | 4.59 M USD | 46.40 M USD | 11.15 M USD | 5000 USD | 33.30 M USD | 17.89 M USD | 16.04 M USD | 9.87 M USD | 20.12 M USD | 1.83 M USD | 2.39 M USD | 30.71 M USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — | — | — | — | -12.78 M USD | -10.77 M USD | -9.63 M USD | -9.08 M USD |
CervoMed Inc. is a biotechnology company focused on developing treatments for neurodegenerative diseases. With a commitment to improving patient outcomes, the company engages in the research and development of innovative therapies that target underlying neurological conditions such as Alzheimer's disease and Parkinson's disease. CervoMed Inc. is recognized for its scientific expertise in neurotherapeutics, exploring promising pathways that could lead to breakthrough solutions. Operating within the highly specialized biotech sector, the company contributes to expanding our understanding of neurobiology and developing targeted interventions. By collaborating with academic institutions, healthcare providers, and industry partners, CervoMed Inc. plays a critical role in advancing medical research and offering hope for patients suffering from debilitating neurological disorders.